Technology Prognosis

tracking technologies before you have to make a decision

Poteligeo (Mogamulizumab-kpkc)

August 9, 2018

Poteligeo (mogamulizumab-kpkc) is an intravenously administered, humanized immunoglobulin G1 monoclonal antibody indicated for the treatment of patients with mycosis fungoides or Sézary syndrome who have failed to adequately respond to at least 1 systemic therapy. Poteligeo targets CC chemokine receptor 4 (CCR4), a novel target for immunotherapy.